BioSpace News Archive

Penumbra, Inc. (NYSE: PEN) today announced that the format for its 2020 Annual Meeting of Stockholders (the “Annual Meeting”) has been changed from an in-person meeting to a virtual-only meeting at the previously announced date and time of June 3, 2020 at 11:00 a.m.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat during the 2020 RBC Capital Markets’ Virtual Global Healthcare Conference on Tuesday, May 19, 2020 at 10:20 a.m. E.D.T.

BioPharmX Corporation (NYSE American: BPMX) (“BioPharmX” or the “Company”), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced that, in anticipation of closing its merger with Timber Pharmaceuticals, it will effect a 1-for-12 reverse stock split of its outstanding common stock.

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), today announced that on May 14, 2020 the Company received a Paragraph IV Notice Letter from Apotex Inc. and Apotex Corp advising Supernus of the submission by Apotex of an Abbreviated New Drug Application to the U.S. Food and Drug Administration (FDA) seeking approval for oxcarbazepine extended-release tablets.

Proteostasis Therapeutics, Inc. (Nasdaq: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced financial results for the first quarter ended March 31, 2020 and provided a corporate update.

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release first quarter 2020 financial results and a Company update after the market closes on Wednesday, May 20, 2020

The COVID-19 pandemic triggered urgent testing needs globally. Given the nature and magnitude of this public health emergency in the USA, testing laboratories in the private sector are “all hands on deck” with frontline medical workers in large scale diagnostics testing for COVID-19 presence.

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the U.S. Food and Drug Administration (FDA) has approved QINLOCK™ (ripretinib) for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.

Nxt-ID, Inc. (NASDAQ: NXTD) (the “Company”), a provider of healthcare devices and services, announces results for the three months ended March 31, 2020.

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today announced financial results for the quarter ended March 31, 2020. Operational Highlights Raised gross proceeds of approximately $5.8 million through the exercise of outstanding warrants in January 2020 Completed enrollment of OP0201